IRWD Live signals | Maximize Profits with Getagraph.com

BUY 98575 min ago

@ $15.52

Issued: 14 Feb 2024 @ 13:33

Return: -48.07%

Previous signal: Feb 13 - 14:42

Previous signal: Sell

Return: 2.37 %

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Stats
Today's Volume	1.97M
Average Volume	4.69M
Market Cap	1.26B
EPS	$0 ( 2024-02-15 )
Next earnings date	( $0.190 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.250
ATR14	$0.0110 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Denner Alexander J	Buy	1 662	Class A Common Stock
2024-03-08	John Minardo	Buy	32 752	Class A Common Stock
2024-03-08	John Minardo	Sell	32 752	Performance-based Restricted Stock Unit
2024-03-08	Emany Sravan Kumar	Buy	37 120	Class A Common Stock
2024-03-08	Emany Sravan Kumar	Sell	37 120	Performance-based Restricted Stock Unit

INSIDER POWER
45.57
Last 100 transactions
Buy: 2 835 189 \| Sell: 1 035 601

Volume Correlation

Long: -0.11 (neutral)

Short: -0.17 (neutral)

Signal:(32.63) Neutral

Ironwood Pharmaceuticals Correlation

10 Most Positive Correlations
IBRX	0.896
BNTX	0.888
GOOD	0.883
CREG	0.883
ERIE	0.881
ORPH	0.88
UTHR	0.878
TIGR	0.877
LLNW	0.874
NAKD	0.874

10 Most Negative Correlations
APOP	-0.924
KTOS	-0.921
SIBN	-0.912
PPD	-0.91
BNIX	-0.905
ARIZ	-0.903
IPAR	-0.902
OXAC	-0.9
WTMA	-0.896
PPYA	-0.895

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ironwood Pharmaceuticals Correlation - Currency/Commodity

0.44
( neutral )

-0.34
( neutral )

0.00
( neutral )

-0.71
( moderate negative )

Ironwood Pharmaceuticals Financials

Annual	2023
Revenue:	$442.74M
Gross Profit:	$441.16M (99.64 %)
EPS:	$-6.45

Q4	2023
Revenue:	$117.55M
Gross Profit:	$117.04M (99.56 %)
EPS:	$-0.00700

Q3	2023
Revenue:	$113.74M
Gross Profit:	$113.23M (99.55 %)
EPS:	$0.0983

Q2	2023
Revenue:	$107.38M
Gross Profit:	$107.11M (99.75 %)
EPS:	$-6.84

Financial Reports:

No articles found.

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.